 Antigens, CD20
"Antigens, CD20" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
| Descriptor ID |
D018951
|
| MeSH Number(s) |
D23.050.301.264.035.120 D23.050.301.264.051.120 D23.101.100.110.120 D23.101.100.150.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD20".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD20 [D23.050.301.264.035.120]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD20 [D23.050.301.264.051.120]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD20 [D23.101.100.110.120]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD20 [D23.101.100.150.120]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD20".
This graph shows the total number of publications written about "Antigens, CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, CD20" by people in Profiles.
-
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von B?dingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc Natl Acad Sci U S A. 2023 01 17; 120(3):e2207291120.
-
Ramos-Gonzalez G, Crum R, Allain A, Agur T, O'Melia L, Staffa S, Burchett SK, Siegele B, Weinberg O, Rodig NM, Fawaz R, Singh TP, Freiberger DA, Bae Kim H. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center. Pediatr Transplant. 2022 08; 26(5):e14268.
-
Ruschil C, Gabernet G, Lepennetier G, Heumos S, Kaminski M, Hracsko Z, Irmler M, Beckers J, Ziemann U, Nahnsen S, Owens GP, Bennett JL, Hemmer B, Kowarik MC. Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses. Front Immunol. 2020; 11:606338.
-
Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, Kornek B, Krupp L, Krysko KM, Nosadini M, Rostasy K, Salzer J, Schreiner T, Tenembaum S, Waubant E. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Mult Scler. 2021 10; 27(12):1814-1822.
-
Martinez-Lage M, Lynch TM, Bi Y, Cocito C, Way GP, Pal S, Haller J, Yan RE, Ziober A, Nguyen A, Kandpal M, O'Rourke DM, Greenfield JP, Greene CS, Davuluri RV, Dahmane N. Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun. 2019 11 29; 7(1):203.
-
Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 07 15; 332:187-197.
-
Babiker HM, Glode AE, Cooke LS, Mahadevan D. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018 Apr; 27(4):407-412.
-
Kao D, Danzer H, Collin M, Gro? A, Eichler J, Stambuk J, Lauc G, Lux A, Nimmerjahn F. A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep. 2015 Dec 22; 13(11):2376-2385.
-
Ozawa MG, Ewalt MD, Gratzinger D. Dasatinib-related Follicular Hyperplasia: An Underrecognized Entity With Characteristic Morphology. Am J Surg Pathol. 2015 Oct; 39(10):1363-9.
-
Chan CT, Sobey CG, Lieu M, Ferens D, Kett MM, Diep H, Kim HA, Krishnan SM, Lewis CV, Salimova E, Tipping P, Vinh A, Samuel CS, Peter K, Guzik TJ, Kyaw TS, Toh BH, Bobik A, Drummond GR. Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension. Hypertension. 2015 Nov; 66(5):1023-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|